Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $168.4 million.

  • Cartesian Therapeutics' Cash from Financing Activities fell 100.03% to -$38,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.2 million, marking a year-over-year decrease of 103.97%. This contributed to the annual value of $168.4 million for FY2024, which is 1381.31% up from last year.
  • Cartesian Therapeutics' Cash from Financing Activities amounted to $168.4 million in FY2024, which was up 1,381.31% from -$13.1 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Cash from Financing Activities ranged from a high of $168.4 million in FY2024 and a low of -$13.1 million during FY2023.
  • Its 3-year average for Cash from Financing Activities is $64.8 million, with a median of $39.2 million in 2022.
  • Per our database at Business Quant, Cartesian Therapeutics' Cash from Financing Activities plummeted by 133.52% in 2023 and then surged by 1,381.31% in 2024.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Cash from Financing Activities stood at $14.4 million in 2020, then spiked by 266.55% to $52.9 million in 2021, then declined by 25.87% to $39.2 million in 2022, then crashed by 133.52% to -$13.1 million in 2023, then surged by 1,381.31% to $168.4 million in 2024.